JP Patent

JP6517401B2 — Ｒｂポジティブ異常細胞増殖に対するｈｓｐｃ温存治療

Assigned to G1 Therapeutics Inc · Expires 2019-05-22 · 7y expired

What this patent protects

Patent listed against trilaciclib-dihydrochloride.

Drugs covered by this patent

trilaciclib-dihydrochloride (TRILACICLIB DIHYDROCHLORIDE)

Patent Metadata

Patent number: JP6517401B2
Jurisdiction: JP
Classification: —
Expires: 2019-05-22
Drug substance claim: No
Drug product claim: No
Assignee: G1 Therapeutics Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.